Daniel D. Shoemaker

2019

In 2019, Daniel D. Shoemaker earned a total compensation of $2.8M as Chief Scientific Officer at Fate Therapeutics, a 111% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$150,938
Option Awards$1,547,898
Salary$375,000
Stock Awards$744,750
Total$2,818,586

Shoemaker received $1.5M in option awards, accounting for 55% of the total pay in 2019.

Shoemaker also received $150.9K in non-equity incentive plan, $375K in salary and $744.8K in stock awards.

Rankings

In 2019, Daniel D. Shoemaker's compensation ranked 4,342nd out of 13,971 executives tracked by ExecPay. In other words, Shoemaker earned more than 68.9% of executives.

ClassificationRankingPercentile
All
4,342
out of 13,971
69th
Division
Manufacturing
1,598
out of 5,701
72nd
Major group
Chemicals And Allied Products
560
out of 2,200
75th
Industry group
Drugs
472
out of 1,886
75th
Industry
Biological Products, Except Diagnostic Substances
103
out of 389
74th
Source: SEC filing on April 21, 2021.

Shoemaker's colleagues

We found three more compensation records of executives who worked with Daniel D. Shoemaker at Fate Therapeutics in 2019.

2019

J Wolchko

Fate Therapeutics

Chief Executive Officer

2019

Bahram Valamehr

Fate Therapeutics

Chief Research and Development Officer

2019

Cindy Tahl

Fate Therapeutics

General Counsel

News

In-depth

You may also like